{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:02:45Z","timestamp":1791442965785,"version":"4.3.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1991,3,1]],"date-time":"1991-03-01T00:00:00Z","timestamp":667785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1991,3]]},"DOI":"10.1007\/bf02316862","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T20:26:39Z","timestamp":1140035199000},"page":"42-48","source":"Crossref","is-referenced-by-count":33,"title":["Perphenazine decanoate andcis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients"],"prefix":"10.1007","volume":"105","author":[{"given":"Kristen","family":"Kistrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Aaes-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels-Erik","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02316862_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-4347(00)81700-4","volume":"183","author":"T Aaes-J\u00f8rgensen","year":"1980","unstructured":"Aaes-J\u00f8rgensen T (1980) Specific high-performance liquid chromatographic method for estimation of thecis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metabolite. J Chromatogr 183:239\u2013245","journal-title":"J Chromatogr"},{"key":"BF02316862_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007691-198512000-00008","volume":"7","author":"AE Balant-Gorgia","year":"1985","unstructured":"Balant-Gorgia AE, Eisele R, Aeschliemann JM, Balant LP, Garrone G (1985) Plasma flupenthixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 7:411\u2013414","journal-title":"Ther Drug Monit"},{"key":"BF02316862_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"BF02316862_CR4","first-page":"229","volume":"38","author":"F Bj\u00f8rndal","year":"1984","unstructured":"Bj\u00f8rndal F, Aaes-J\u00f8rgensen T (1984) Serumconcentration in acute paranoid psychoses treated withcis(Z)-clopenthixol. Nord Psychiatr Tidsskr 38:229\u2013233","journal-title":"Nord Psychiatr Tidsskr"},{"key":"BF02316862_CR5","first-page":"306","volume":"53","author":"L Bolvig Hansen","year":"1977","unstructured":"Bolvig Hansen L, Larsen N-E (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:306\u2013309","journal-title":"Psychopharmacology"},{"key":"BF02316862_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF00432736","volume":"74","author":"L Bolvig Hansen","year":"1981","unstructured":"Bolvig Hansen L, Larsen N-E, Vesterg\u00e5rd P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306\u2013309","journal-title":"Psychopharmacology"},{"key":"BF02316862_CR7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00432245","volume":"78","author":"L Bolvig Hansen","year":"1982","unstructured":"Bolvig Hansen L, Larsen N-E, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychosis. Psychopharmacology 78:112\u2013115","journal-title":"Psychopharmacology"},{"key":"BF02316862_CR8","first-page":"94","volume":"2","author":"FWA Browne","year":"1988","unstructured":"Browne FWA, Cooper SJ, Wilson R, King DJ (1988) Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients. J Pharmacol 2:94\u2013103","journal-title":"J Pharmacol"},{"key":"BF02316862_CR9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/schbul\/9.4.533","volume":"9","author":"WT Carpenter","year":"1983","unstructured":"Carpenter WT, Heinrichs DW (1983) Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 9:533\u2013542","journal-title":"Schizophr Bull"},{"issue":"suppl 2","key":"BF02316862_CR10","first-page":"426","volume":"13","author":"MI Herz","year":"1990","unstructured":"Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV (1990) Intermittent vs maintenance medication in schizophrenia. Clin Neuropharmacol 13 [suppl 2]:426\u2013427","journal-title":"Clin Neuropharmacol"},{"key":"BF02316862_CR11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/0024-3205(78)90580-5","volume":"23","author":"A J\u00f8rgensen","year":"1978","unstructured":"J\u00f8rgensen A (1978) A sensitive and specific radioimmunoassay forcis(Z)-flupenthixol in human serum. Life Sci 23:1533\u20131542","journal-title":"Life Sci"},{"key":"BF02316862_CR12","first-page":"1103","volume-title":"Psychopharmacology: the third generation of progress","author":"JM Kane","year":"1987","unstructured":"Kane JM, Liebermann JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1103\u20131109"},{"key":"BF02316862_CR13","first-page":"533","volume":"21","author":"JM Kane","year":"1985","unstructured":"Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, Borenstein M (1985) High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacol Bull 21:533\u2013537","journal-title":"Psychopharmacol Bull"},{"key":"BF02316862_CR14","first-page":"493","volume":"38","author":"L Kirk","year":"1984","unstructured":"Kirk L, Bilde A, Stauning JA, Ahrensburg B, Petersen E, J\u00f8rgensen A (1984) Serum concentrations ofcis(z)-flupenthixol in patients under maintenance treatment withcis(z)-flupenthixol decanoate. Nord Psychiatr Tidsskr 38:493\u2013505","journal-title":"Nord Psychiatr Tidsskr"},{"issue":"suppl","key":"BF02316862_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1985.tb08538.x","volume":"72","author":"P Knudsen","year":"1985","unstructured":"Knudsen P, Hansen LB, H\u00f8jholdt K, Larsen N-E (1985) Long-term depot treatment with perphenazine decanoate I. Acta Psychiatr Scand (suppl) 72:29\u201340","journal-title":"Acta Psychiatr Scand"},{"key":"BF02316862_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0378-4347(00)84037-2","volume":"341","author":"N-E Larsen","year":"1985","unstructured":"Larsen N-E, Bolvig Hansen L, Knudsen P (1985) Quantitative determination of perphenazine and its dealcylated metabolites using high-performance liquid chromatographic method. J Chromatogr 341:244\u2013250","journal-title":"J Chromatogr"},{"key":"BF02316862_CR17","volume-title":"Predictors of relapse in schizophrenia","author":"JA Liebermann","year":"1986","unstructured":"Liebermann JA, Kane JM (1986) Predictors of relapse in schizophrenia. American Psychiatric Press, Washington"},{"key":"BF02316862_CR18","doi-asserted-by":"crossref","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) Side effects of neuroleptics: The UKU side effect rating scale. Acta Psychiatr Scand 76 [suppl 334]","DOI":"10.1037\/t64050-000"},{"key":"BF02316862_CR19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archpsyc.1987.01800180028005","volume":"44","author":"SR Marder","year":"1987","unstructured":"Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 44:518\u2013521","journal-title":"Arch Gen Psychiatry"},{"key":"BF02316862_CR20","first-page":"1341","volume-title":"Psychopharmacology: the third generation of progress","author":"K Midha","year":"1987","unstructured":"Midha K, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1341\u20131351"},{"key":"BF02316862_CR21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"J Overall","year":"1962","unstructured":"Overall J, Gorham D (1962) Brief Psychiatric Rating Scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"BF02316862_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00432123","volume":"80","author":"JK Saikia","year":"1983","unstructured":"Saikia JK, J\u00f8rgensen A (1983) Steady-state serum concentrations aftercis(z)-flupenthixol decanoate in Viscoleo. Psychopharmacology 80:371\u2013373","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02316862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02316862\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02316862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T17:57:27Z","timestamp":1558029447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02316862"}},"subtitle":["Serum levels at the minimum effective dose"],"short-title":[],"issued":{"date-parts":[[1991,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991,3]]}},"alternative-id":["BF02316862"],"URL":"https:\/\/doi.org\/10.1007\/bf02316862","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,3]]}}}